论文部分内容阅读
目的 :探讨端粒酶在肾母细胞瘤中的表达及其临床意义。方法 :采用TRAP法检测 30例肾母细胞瘤、10例瘤旁肾组织和 4例胚胎肾组织的端粒酶表达情况 ,观察端粒酶阳性与该瘤的临床分期、病理分型、预后之间的关系。结果 :2 4例肾母细胞瘤端粒酶为阳性 ,阳性率占 80 %。 10例瘤旁肾组织均为阴性 ,4例胚胎肾组织为阳性 ;Ⅰ期患儿端粒酶阳性所占比例明显低于其它 3期 (P <0 .0 5 ) ;上皮型端粒酶阳性与其它 3型有显著差异 (P <0 .0 1) ;端粒酶阳性患儿生存率低于阴性患儿 (P <0 .0 5 )。结论 :肾母细胞瘤组织中 ,端粒酶阳性表达较高 ,特异性强 ,提示端粒酶阳性可成为判定肾母细胞瘤预后的一项新指标。
Objective: To investigate the expression of telomerase in Wilms’ tumor and its clinical significance. Methods: The TRAP method was used to detect the expression of telomerase in 30 cases of nephroblastoma, 10 cases of para-tumor kidney tissue and 4 cases of embryonic kidney tissue. The telomerase positive was observed with the clinical stage, pathological type, prognosis Relationship between. Results: 24 cases of nephroblastoma telomerase positive, the positive rate of 80%. 10 cases of para-renal tissue were negative, 4 cases of embryonic kidney tissue was positive; stage Ⅰ telomerase-positive rate was significantly lower than the other 3 (P <0. 05); epithelial telomerase positive There was a significant difference (P <0.01) with other type 3; the survival rate of telomerase positive children was lower than that of negative children (P <0.05). Conclusion: The positive expression and high specificity of telomerase in nephroblastoma suggest that telomerase positive may be a new indicator to judge the prognosis of nephroblastoma.